CitratPlasma

CitratPlasma is a synthetic or bioengineered plasma alternative designed to emulate the properties of natural blood plasma. Its primary function is to serve as a volume expander in medical treatments, particularly in cases of hemorrhagic shock, dehydration, or plasma exchange therapies. CitratPlasma is formulated to deliver essential ions, proteins, and other plasma components, facilitating fluid balance and supporting physiological functions without the use of donor blood donors.

The composition of CitratPlasma typically includes a balanced mixture of electrolytes such as sodium, potassium, calcium, and chloride, which mimic the electrolyte profile of natural plasma. It may also contain plasma proteins like albumin or synthetic variants that help maintain osmotic pressure. The formulation is often stabilized with citrate, which chelates calcium ions to prevent clotting during storage and administration. As a citrate-based solution, CitratPlasma aids in preventing unwanted coagulation within the circulatory system during medical procedures.

One notable feature of CitratPlasma is its potential to be produced via biotechnological processes, allowing for consistent quality and reduced reliance on human plasma donations. The use of synthetic alternatives supports safety by minimizing risks of transfusion-transmissible infections and immune reactions.

Research into CitratPlasma explores its applications in trauma care, surgery, and intensive care units. Its design aligns with biomimetic principles by replicating natural plasma’s functions through engineered materials, aiming for compatibility, safety, and efficiency in medical use.

While CitratPlasma remains under development and evaluation, its emergence reflects ongoing advancements in biomedical engineering, offering promising solutions for blood substitute needs.